A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results (Q34142430)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

31 July 2017

A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results (English)

1 reference

Europe PubMed Central

31 July 2017

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

cervix uterine cancer

1 reference

based on heuristic

inferred from title

author name string

Jaime Coronel

1

1 reference

Europe PubMed Central

31 July 2017

Lucely Cetina

2

1 reference

Europe PubMed Central

31 July 2017

Irlanda Pacheco

3

1 reference

Europe PubMed Central

31 July 2017

Catalina Trejo-Becerril

4

1 reference

Europe PubMed Central

31 July 2017

Aurora González-Fierro

5

1 reference

Europe PubMed Central

31 July 2017

Erick de la Cruz-Hernandez

6

1 reference

Europe PubMed Central

31 July 2017

Enrique Perez-Cardenas

7

1 reference

Europe PubMed Central

31 July 2017

Lucia Taja-Chayeb

8

1 reference

Europe PubMed Central

31 July 2017

Daymi Arias-Bofill

9

1 reference

Europe PubMed Central

31 July 2017

Myrna Candelaria

10

1 reference

Europe PubMed Central

31 July 2017

Silvia Vidal

11

1 reference

Europe PubMed Central

31 July 2017

Alfonso Dueñas-González

12

1 reference

Europe PubMed Central

31 July 2017

publication date

8 October 2010

1 reference

Europe PubMed Central

31 July 2017

Medical Oncology

1 reference

Europe PubMed Central

31 July 2017

28 Suppl 1

1 reference

Europe PubMed Central

31 July 2017

S540-6

1 reference

Europe PubMed Central

31 July 2017

https://scigraph.springernature.com/pub.10.1007/s12032-010-9700-3

0 references

Epigenetics of cervical cancer. An overview and therapeutic perspectives

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9700-3

21 January 2018

Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9700-3

21 January 2018

Pharmacotherapy options for locally advanced and advanced cervical cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9700-3

21 January 2018

The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9700-3

21 January 2018

Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9700-3

21 January 2018

Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9700-3

21 January 2018

Epigenetic and HIF-1 regulation of stanniocalcin-2 expression in human cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9700-3

21 January 2018

Association between CpG island methylation of the WWOX gene and its expression in breast cancers

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9700-3

21 January 2018

Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9700-3

21 January 2018

A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9700-3

21 January 2018

A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9700-3

21 January 2018

Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9700-3

21 January 2018

A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9700-3

21 January 2018

Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9700-3

21 January 2018

The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9700-3

21 January 2018

Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9700-3

21 January 2018

Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9700-3

21 January 2018

Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9700-3

21 January 2018

Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9700-3

21 January 2018

The effects of DNA methylation and histone deacetylase inhibitors on human papillomavirus early gene expression in cervical cancer, an in vitro and clinical study

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9700-3

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9700-3

21 January 2018

Hydralazine target: from blood vessels to the epigenome

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9700-3

21 January 2018

Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9700-3

21 January 2018

Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9700-3

21 January 2018

Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9700-3

21 January 2018

Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9700-3

21 January 2018

Molecular modeling and molecular dynamics studies of hydralazine with human DNA methyltransferase 1.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9700-3

21 January 2018

Activation and transposition of endogenous retroviral elements in hypomethylation induced tumors in mice.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9700-3

21 January 2018

Induction of Tumors in Mice by Genomic Hypomethylation

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9700-3

21 January 2018

Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9700-3

21 January 2018

Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9700-3

21 January 2018

Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9700-3

21 January 2018

Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9700-3

21 January 2018

Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9700-3

21 January 2018

A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9700-3

21 January 2018

Dual targeting of epigenetic therapy in cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20931299

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Histone deacetylases and epigenetic therapies of hematological malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/20931299

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20931299

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20931299

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12032-010-9700-3

1 reference

Europe PubMed Central

31 July 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

31 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34142430&oldid=2043545958"